MARKET

ARNA

ARNA

Arena Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

80.50
-0.06
-0.07%
After Hours: 81.75 +1.25 +1.55% 16:42 01/15 EST
OPEN
80.00
PREV CLOSE
80.56
HIGH
81.81
LOW
79.00
VOLUME
471.29K
TURNOVER
--
52 WEEK HIGH
90.19
52 WEEK LOW
32.95
MARKET CAP
4.68B
P/E (TTM)
-11.4136
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Anti-Obesity Prescription Drugs Market Size 2020 Analysis and In-depth Research on Trends, Emerging Growth Factors and Forecast to 2024
Jan 12, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Growing demand for obesity is one of the...
The Express Wire · 4d ago
8-K: ARENA PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- false 0001080709 0001080709 2021-01-11 2021-01-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
Narcolepsy Market By Industry Key Players, Trends, Sales, Supply, Demand, Analysis & Forecast till 2023
Jan 11, 2021 (Heraldkeepers) -- Market Analysis The global narcolepsy market is likely to grow at an 8.2% CAGR between 2017- 2023, according to the recent...
Heraldkeepers · 5d ago
Arena Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 13
, /PRNewswire/ -- (Nasdaq: ARNA) today announced that , the Company's President and Chief Executive Officer, is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on , at .
PR Newswire - PRF · 12/22/2020 21:01
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
, /PRNewswire/ --  (Nasdaq: ARNA) today announced that on , the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 141,975 shares of its common stock and 2,460 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of , and were granted as inducements material to the new employees entering into employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).
PR Newswire - PRF · 12/18/2020 18:01
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on December 15, 2020, the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 141,975 shares of its common stock and 2,460 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of December 15, 2020, and were granted as inducements material to the new employees entering into employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).
PR Newswire · 12/18/2020 18:01
Is ARNA A Good Stock To Buy Now?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Insider Monkey · 12/15/2020 00:16
The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna's COVID Vaccine And Drugs From Amgen, MacroGenics
Biotech stocks advanced for a third straight week, defying the broader market weakness. The space got solid support from positive stock reactions to presentations made at hematology and breast cancer conferences.
Benzinga · 12/13/2020 14:14
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARNA. Analyze the recent business situations of Arena Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARNA stock price target is 94.79 with a high estimate of 116.00 and a low estimate of 76.00.
EPS
Institutional Holdings
Institutions: 378
Institutional Holdings: 56.27M
% Owned: 96.74%
Shares Outstanding: 58.16M
TypeInstitutionsShares
Increased
81
5.46M
New
67
-220.94K
Decreased
91
6.27M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/Independent Director
Tina Nova
President/Chief Executive Officer/Director
Amit Munshi
Chief Financial Officer/Executive Vice President
Laurie Stelzer
Executive Vice President/General Counsel/Secretary
Joan Schmidt
Executive Vice President
Vincent Aurentz
Executive Vice President
Robert Lisicki
Senior Vice President
Paul Streck
Director
Katharine Knobil
Independent Director
Jayson Dallas
Independent Director
Oliver Fetzer
Independent Director
Kieran Gallahue
Independent Director
Jennifer Jarrett
Independent Director
Garry Neil
Independent Director
Manmeet Soni
Independent Director
Randall Woods
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ARNA
Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Arena Pharmaceuticals, Inc. stock information, including NASDAQ:ARNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARNA stock methods without spending real money on the virtual paper trading platform.